Traynor Capital Management Inc. increased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 22.7% during the second quarter, Holdings Channel reports. The institutional investor owned 6,479 shares of the biopharmaceutical company’s stock after buying an additional 1,200 shares during the period. Traynor Capital Management Inc.’s holdings in Alnylam Pharmaceuticals were worth $516,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently added to or reduced their stakes in ALNY. FMR LLC increased its stake in Alnylam Pharmaceuticals by 0.3% in the first quarter. FMR LLC now owns 12,907,883 shares of the biopharmaceutical company’s stock valued at $661,530,000 after buying an additional 35,803 shares in the last quarter. Wellington Management Group LLP increased its stake in Alnylam Pharmaceuticals by 0.3% in the first quarter. Wellington Management Group LLP now owns 12,041,179 shares of the biopharmaceutical company’s stock valued at $617,111,000 after buying an additional 31,208 shares in the last quarter. Vanguard Group Inc. increased its stake in Alnylam Pharmaceuticals by 3.7% in the first quarter. Vanguard Group Inc. now owns 5,660,213 shares of the biopharmaceutical company’s stock valued at $290,086,000 after buying an additional 200,890 shares in the last quarter. BlackRock Inc. increased its stake in Alnylam Pharmaceuticals by 34,755.2% in the first quarter. BlackRock Inc. now owns 4,746,234 shares of the biopharmaceutical company’s stock valued at $243,242,000 after buying an additional 4,732,617 shares in the last quarter. Finally, Baillie Gifford & Co. increased its stake in Alnylam Pharmaceuticals by 0.5% in the first quarter. Baillie Gifford & Co. now owns 3,334,511 shares of the biopharmaceutical company’s stock valued at $170,894,000 after buying an additional 16,489 shares in the last quarter. 88.96% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) traded up 0.18% during trading on Friday, hitting $76.08. 33,935 shares of the company traded hands. Alnylam Pharmaceuticals, Inc. has a 52-week low of $31.38 and a 52-week high of $86.92. The company’s 50-day moving average is $81.11 and its 200 day moving average is $61.63. The firm’s market cap is $6.70 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the consensus estimate of ($1.22) by $0.12. The company had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. Alnylam Pharmaceuticals had a negative return on equity of 48.01% and a negative net margin of 670.81%. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.05) earnings per share. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post ($5.23) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.dailypolitical.com/2017/08/11/alnylam-pharmaceuticals-inc-nasdaqalny-shares-bought-by-traynor-capital-management-inc.html.

ALNY has been the topic of several research analyst reports. Cowen and Company reissued a “buy” rating and set a $100.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, July 11th. Vetr downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 target price on the stock. in a research report on Monday, May 15th. Piper Jaffray Companies set a $118.00 target price on shares of Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, May 15th. Barclays PLC boosted their target price on shares of Alnylam Pharmaceuticals from $50.00 to $70.00 and gave the stock an “equal weight” rating in a research report on Thursday. Finally, Credit Suisse Group boosted their target price on shares of Alnylam Pharmaceuticals from $90.00 to $96.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 27th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $81.74.

In other Alnylam Pharmaceuticals news, VP Michael Mason sold 9,375 shares of the business’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $70.00, for a total transaction of $656,250.00. Following the sale, the vice president now directly owns 5,625 shares in the company, valued at approximately $393,750. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Akshay Vaishnaw sold 43,750 shares of Alnylam Pharmaceuticals stock in a transaction on Monday, May 15th. The stock was sold at an average price of $65.00, for a total value of $2,843,750.00. Following the transaction, the senior vice president now directly owns 43,047 shares of the company’s stock, valued at approximately $2,798,055. The disclosure for this sale can be found here. Insiders have sold a total of 64,125 shares of company stock worth $4,325,000 over the last 90 days. Insiders own 4.30% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.